Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by fredgoodwinsonon Jan 17, 2020 7:14am
209 Views
Post# 30563981

Clinical Hold Complete Response

Clinical Hold Complete Response

Might recall that on the 29th of November 2019 we were told:

 

‘Theralase is currently addressing these deficiencies and expects to provide the FDA with a Clinical Hold Complete Response prior to December 31, 2019 for review by the FDA.’

 

It was not until the 7th of January 2020 that we were then told that the Clinical Hold Complete Response might not in fact be submitted until as late as the 31st of March 2020.

 

Had they initially misunderstood the nature of the required response? Did the answer to the question get more and more difficult each time they read it?

 

Highly improbable - that`s not the way our geniuses do Science.

 

Looks much more like they had a re-think and decided that the timing of the Clinical Hold Complete Response would be tactical and it may prove that they do not wish to publish anything at all positive - and particularly an IND approval - before the 3rd of March.

 

When might they put the Complete Response in? The FDA must respond to one within 30 days` but could do so much sooner.To be safe they may decide not to submit until late Feb and for the same reason we might not hear any other positive news before the 3rd of March either.

 
Bullboard Posts